Get the Stockscreener App
57.31
2.32%
1.30
After Hours:
57.31
Ani Pharmaceuticals Inc stock is traded at $57.31, with a volume of 157.55K.
It is up +2.32% in the last 24 hours and down -0.90% over the past month.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
See More
Previous Close:
$56.01
Open:
$55.6
24h Volume:
157.55K
Relative Volume:
0.45
Market Cap:
$1.20B
Revenue:
$486.82M
Net Income/Loss:
$18.78M
P/E Ratio:
-119.40
EPS:
-0.48
Net Cash Flow:
$100.45M
1W Performance:
-2.88%
1M Performance:
-0.90%
6M Performance:
-14.78%
1Y Performance:
-12.41%
1-Day Range:
$55.55
$57.67
1-Week Range:
$55.55
$60.44
52-Week Range:
$48.20
$70.81
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(218) 634-3500
Address
210 MAIN STREET WEST, BAUDETTE, MN
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
ANI Pharmaceuticals to Present at Guggenheim's Inaugural - GlobeNewswire
ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November - StockTitan
F M Investments LLC Buys Shares of 61,782 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals Stock: Acting Like It Is Being Acquired (NASDAQ:ANIP) - Seeking Alpha
Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline - Yahoo Finance
ANI Pharmaceuticals (ANIP) to Release Quarterly Earnings on Friday - MarketBeat
ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET - GlobeNewswire
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Down 9.7% in October - MarketBeat
Assenagon Asset Management S.A. Grows Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06% - GlobeNewswire
ANI Pharmaceuticals introduces generic Estradiol Gel By Investing.com - Investing.com South Africa
ANI Pharmaceuticals introduces generic Estradiol Gel - Investing.com
ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024 - The Manila Times
ANI Pharmaceuticals to Present New Data Highlighting - GlobeNewswire
ANI Pharmaceuticals price target raised to $62 from $60 at Truist - Yahoo Finance
Critical Insights From ANI Pharmaceuticals Analyst Ratings: What You Need To Know - Benzinga
ANI Pharmaceuticals (NASDAQ:ANIP) PT Raised to $62.00 at Truist Financial - MarketBeat
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? - Yahoo Finance
Avadel Obtains FDA Nod for Label Expansion Of Narcolepsy Drug Lumryz - Benzinga
Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? - Yahoo Finance
ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue? - Yahoo Finance
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $14,297.50 in Stock - MarketBeat
Ani Pharmaceuticals' sr. vp sells $14,297 in stock By Investing.com - Investing.com Canada
Ani Pharmaceuticals' sr. vp sells $14,297 in stock - Investing.com India
ANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Piper Sandler - Defense World
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential - Yahoo Finance
ANI Pharmaceuticals And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency
ANI Pharma stock earns bull at Piper Sandler (NASDAQ:ANIP) - Seeking Alpha
Piper Sandler Initiates Coverage on ANI Pharmaceuticals (NASDAQ:ANIP) - MarketBeat
Peeling Back The Layers: Exploring ANI Pharmaceuticals Through Analyst Insights - Benzinga
ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market - Seeking Alpha
While shareholders of ANI Pharmaceuticals (NASDAQ:ANIP) are in the black over 3 years, those who bought a week ago aren't so fortunate - Simply Wall St
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Acquired by Millennium Management LLC - MarketBeat
Algert Global LLC Decreases Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance - GlobeNewswire
Dimensional Fund Advisors LP Boosts Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Down 8.3% in September - MarketBeat
Maverick Capital Ltd. Has $1.18 Million Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? - Yahoo Finance
Drugs for Arrhythmia Market Demand and Business Outlook | Sanofi, Boehringer Ingelheim Pharmaceuticals, Inc, ANI Pharmaceuticals – Cauverynews - Cauverynews
ANI Pharmaceuticals launches generic Ketoconazole Shampoo - Investing.com India
ANI Pharmaceuticals launches generic Ketoconazole Shampoo By Investing.com - Investing.com Canada
ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2% - The Manila Times
American Century Companies Inc. Purchases 49,717 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Quotes, Forecast and News Summary - Benzinga
Renaissance Technologies LLC Raises Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
It makes sense and dollars to buy ANI Pharmaceuticals Inc (ANIP) stock - SETE News
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.88%
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):